Curtis L. Scribner

Dr. Scribner is a board certified internal medicine specialist with long experience in drug development as a clinical investigator, regulatory reviewer, and strategic product life cycle consultant. He has extensive experience in virology and viral diseases, oncology, hepatology, infectious disease, rheumatology, immunology, very rare and Orphan diseases and gene therapy. Dr. Scribner was at the Center for Biologics Evaluation and Research (CBER), FDA, for 10 years, reviewing all phases of clinical development in a wide breadth of areas (including blood, plasma, recombinant proteins, cells, tissues, vaccines). Dr. Scribner was also Chief Regulatory Officer at a venture-based drug, biologic and combination development company (BioMedicines/Intarcia). He has more than 25 years of experience as a consultant to drugs and biologics companies working on everything from discovery and preclinical models through clinical trials, especially early stage clinical trials, Data Safety Monitoring Committees, and strategic and operational regulatory interactions in the US (FDA) and Europe (EMA and Member States). Dr. Scribner received his M.D. from the University of Colorado College of Medicine, an MBA from the University of Maryland School of Business, and a B.A. from Grinnell College.